Neuroactive steroids and methods of use thereof
US-2016031930-A1 · Feb 4, 2016 · US
Neuroactive steroids and methods of use thereof
US10227375B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10227375-B2 |
| Application number | US-201815917263-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 9, 2018 |
| Priority date | Mar 13, 2013 |
| Publication date | Mar 12, 2019 |
| Grant date | Mar 12, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R 1 , R 2 , R 3a , R 3b , R 4 , R 5a , R 5b , R 6a , and R 6b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of the structure: where the absolute stereochemistry of the compound is as shown. 2. A pharmaceutically acceptable salt of a compound, wherein the compound is of the structure where the absolute stereochemistry of the compound is as shown. 3. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable excipient. 4. A pharmaceutical composition comprising a pharmaceutically acceptable salt according to claim 2 and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Otologicals · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10227375B2 cover?
- Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R 1 , R 2 , R 3a , R 3b , R 4 , R 5a , R 5b , R 6a , and R 6b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions.
- Who is the assignee on this patent?
- Sage Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07J9/005. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).